Published in:
Open Access
01-12-2013 | Review
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Authors:
Li Shi, Shaohua Chen, Lijian Yang, Yangqiu Li
Published in:
Journal of Hematology & Oncology
|
Issue 1/2013
Login to get access
Abstract
T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. We are beginning to understand the power of co-inhibitors in the context of lymphocyte homeostasis and the pathogenesis of leukemia, which involves several newly described co-inhibitory pathways, including the programmed death-1 (PD-1) and PD-1 ligand (PD-L1) pathway. The aim of this review is to summarize the PD-1 and PD-L1 biological functions and their alterative expression in hematological malignancies. The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed.